Inozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1 Deficiency Phase 1/2 Clinical Trial

Excerpt from the Press Release:

BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced the first self-administration of INZ-701 in the open-label Phase 2 extension portion of the ongoing Phase 1/2 clinical trial of INZ-701 in adult patients with ENPP1 Deficiency.

The implementation of self-administration of INZ-701 followed Inozyme’s submission of a protocol amendment to the U.S. Food and Drug Administration (FDA) and approval of a protocol amendment submitted to the German Federal Institute for Drugs and Medical Devices (BfArM). The Company has also submitted documentation to additional ex-U.S. regulatory agencies to allow self-administration. These submissions were supported by preliminary safety data from the ongoing trial.

“This is a significant milestone for a product candidate at this stage of its clinical and regulatory pathway and we believe highlights the safety profile of INZ-701 to date in our ongoing Phase 1/2 clinical trial,” said Kurt Gunter, M.D., Inozyme’s senior vice president and chief medical officer. “Self-administration opens up a convenient dosing option for patients in the Phase 2 extension. The extension portion of the trial is designed to provide important long-term safety and clinical data and support the development of INZ-701 as the first potential approved therapy for ENPP1 Deficiency.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release